Camel heavy chain antibodies against prostate-specific membrane antigen

Hybridoma

Volumn 31, Issue 6, 2012, Pages 424-429

  Evazalipour, Mehdi ^a,b   Tehrani, Bahram Soltani ^b   Abolhassani, Mohsen ^a   Morovvati, Hamid ^b   Omidfar, Kobra ^c  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CAMEL HEAVY CHAIN ANTIBODY; IMMUNOGLOBULIN G; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN A; PROTEIN G; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ARTICLE; BINDING AFFINITY; CAMEL; DROMEDARY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOCYTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; ANTIGENS, SURFACE; CAMELS; CELL LINE, TUMOR; CHROMATOGRAPHY, AFFINITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; MALE; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; PROTEIN BINDING; SERUM ALBUMIN, BOVINE;

CAMELUS DROMEDARIUS;

EID: 84871264344     PISSN: 15540014     EISSN: 15578348     Source Type: Journal    
DOI: 10.1089/hyb.2012.0048     Document Type: Article

References (38)

1. Djavan B, Remzi M, Zlotta A, Seitz C, Snow P, and Mar-berger M: Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 2002;20:921-929.
2. Israeli RS, Powell CT, Corr JG, Fair WR, and Heston WD: Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:807-811.
3. Chang SS, Gaudin PB, Reuter VE, and Heston WDW: Prostate-specific membrane antigen: present and future applications. Urology 2000;55:622-629.
4. Sam S, and Chang MD: Overview of prostate-specific membrane antigen. Rev Urol 2004;6:S13-S18.
5. Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM, Wang CY, and Haas GP: Expression of prostate specific membrane antigen in normal and malignant human tissues. World J Surg 2006;30:628-636.
6. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, and Gaudin PB: Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674-2681.
7. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, and Gaudin PB: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-3198.
8. Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Mühlmann G, Ofner D, Zelger B, Ensinger C, Yang XJ, Geley S, Margreiter R, and Bander NH: Prostate specific membrane antigen expression in the neovasculature of gastric and co-lorectal cancers. Hum Pathol 2009;40:1754-1761.
9. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, and Bander NH: Phase I trial of yttrium-90-labeled antiprostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004;22:2522-2531.
10. Ross JS, Gray K, Gray GS, Worland PJ, and Rolfe M: Anticancer antibodies. Am J Clin Pathol 2003;119:472-485.
11. Elsasser-Beile U, Buhler P, and Wolf P: Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets 2009;10:118-125.
12. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, and Bander NH: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57:3629-3634.
13. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, and Bander NH: Constitutive and antibody induced internalization of prostate-specific membrane antigen. Cancer Res 1998;58:4055-4060.
14. McDevitt MR, Barendswaard E, Ma D, Curcio MJ, Sgouros G, Ballangrud AM, Yang WH, Finn RD, Pellegrini V, Geer-lings MW Jr, Lee M, Brechbiel MW, Bander NH, Cordon-Cardo C, and Scheinberg DA: An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000;60:6095-6100.
15. Ballangrud AM, Yang WH, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, Ma D, Bander NH, Scheinberg DA, and Sgouros G: Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res 2001;61:2008-2014.
16. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, and Bander NH: Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003; 44:610-617.
17. Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Val-labhajosula S, Goldsmith SJ, Ross JS, and Bander NH: Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007;25:540-547.
18. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Val-labhajosula S, and Goldsmith SJ: Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23:4591-4601.
19. Henry MD, Wen S, Silva MD, Chandra S, Milton M, and Worland PJ: A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 2004;64: 7995-8001.
20. Kuroda K, Liu H, Kim S, Guo M, Navarro V, and Bander NH: Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity. Prostate 2010;70:1286-1294.
21. Mays TA, Sarantopoulos J, Tolcher A, Lowy I, Preston G, Levy E, Oslund M, Manchen E, Kelly A, and Stadler W: MDX-070, a human anti-plasma antibody, administered as either a single dose or as multiple doses to patients with hormone-refractory prostate cancer. J Clin Oncol 2006;24: 14549.
22. Nakajima T, Mitsunaga M, Bander NH, Heston WD, Choyke PL, and Kobayashi H: Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. Bioconjug Chem 2011;22:1700-1705.
23. Alt K, Wiehr S, Ehrlichmann W, Reischl G, Wolf P, Pichler BJ, Elsässer-Beile U, and Bü hler P: High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA. Prostate 2010;70:1413-1421.
24. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, and Senter PD: Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-784.
25. Fracasso G, Bellisola G, Cingarlini S, Castelletti D, Prayer-Galetti T, Pagano F, Tridente G, and Colombatti M: Antitumor effects of toxins targeted to the prostate specific membrane antigen. Prostate 2002;53:9-23.
26. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, and Hamers R: Naturally occurring antibodies devoid of light chains. Nature 1993;363:446-448.
27. Nguyen VK, Desmyter A, and Muyldermans S: Functional heavy chain antibodies in Camelidae. Adv Immunol 2001; 79:261-295.
28. Omidfar K, Rasaee MJ, Modjtahedi H, Forouzandeh M, Taghikhani M, Bakhtiari A, Paknejad M, and Kashanian S: Production and characterization of a new antibody specific for the mutant EGF receptor, EGFRvIII, in Camelus bac-trianus. Tumour Biol 2004;25:179-187.
29. Rahbarizadeh F, Rasaee MJ, Forouzandeh M, Allameh A, Sarrami R, Nasiry H, and Sadeghizadeh M: The production and characterization of novel heavy-chain antibodies against the tandem repeat region of MUC1 mucin. Immunol Invest 2005;34:431-52.
30. Desmyter A, Decanniere K, Muyldermans S, and Wyns L: Antigen specificity and high affinity provided by one single loop of a camel single domain antibody. J Biol Chem 2001; 276:26285-26290.
31. Omidfar K, Rasaee MJ, Modjtahedi H, Forouzandeh M, Taghikhani M, and Golmakani N: Production of a novel camel single domain antibody specific for the type III mutant EGFR.Tumour Biol 2004;25:296-305.
32. Omidfar K, and Shirvani Z: Single domain antibodies: a new concept for EGFR and EGFRvIII targeting. DNA Cell Biol 2012;31(6):1015-1026.
33. Omidfar K, Rasaee MJ, Kashanian S, Paknejad M, and Bathaie Z: Studies of thermostability in camelusbactrianus (Bactrian camel) single-domain antibody specific for the mutant epidermal-growth-factor receptor expressed by Pi-chia. Biotechnol Appl Biochem 2007;46:41-49.
34. Omidfar K, Moinfar Z, Sohi AN, Tavangar SM, Haghpanah V, Heshmat R, Kashanian S, and Larijani B: Expression of EGFRvIII in thyroid carcinoma: immunohistochemical study by camel antibodies. Immunol Invest 2009;38:165-180.
35. Beatty JD, Beatty BG, and Vlahos WG: Measurement of monoclonal affinity by noncompetitive enzyme immunoas-say. J Immunol Methods 1987;100:137-179.
36. Paknejad M, Rasaee MJ, Tehrani FK, Kashanian S, Moha-gheghi MA, Omidfar K, and Bazl MR: Production of monoclonal antibody, PR81, recognizing the tandem repeat region of MUC1 mucin. Hybrid Hybridomics 2003;22: 153-158.
37. Mohammadnejad J, Rasaee MJ, Saqhafi B, Rajabibazl M, Rahbarizadeh F, Omidfar K, and Paknejad M: A new competitive enzyme linked immunosorbent assay (MRP83-CA15-3) for MUC1 measurement in breast cancer. Immunoassay Immunochem 2006;27:139-149.
38. Muyldermans S, Atarhouch T, Saldanha J, Barbosa JA, and Hamers R: Sequence and structure of VH domain from naturally occurring camel heavy immunoglobulins lacking light chains. Prot Engine 1994;7:1129-1131.